Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

NCT01554618 on ClinicalTrials.gov · last registry update 2021-11-30

A small phase 3 — 84 participants, against a typical 424. The sponsor logged completion for 6 May 2020. Primary outcome, as filed: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) to Week 24 (Controlled Assessment Period). exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 84
Started: 2011-12-02
Primary completion: 2020-05-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) to Week 24 (Controlled Assessment Period)

Conditions studied

Children and Adolescent With Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.